On 29. January 2021, "COVID-19 Vaccine AstraZeneca" was authorised in the European Union as the third vaccine against SARS-CoV2.

This issue of RMS NEWS again contains current and relevant news for our applicants for marketing authorisations with Austria as RMS.

On 06. January 2021, "COVID-19 Vaccine Moderna" was authorised in the European Union as the second vaccine against SARS-CoV2.

Based on the recommendation by the European Medicines Agency (EMA), the European Commission issued the marketing authorisation for the COVID-19 vaccine Comirnaty (BioNTech).

In Austria, adverse reactions can be voluntarily reported directly to the Federal Office for Safety in Health Care (BASG) by patients as well as their relatives.

An update on CCP (COVID-19 Convalescent Plasma) has been forwarded by the European Commission to the Federal Office for Safety in Health Care.

MMS (Miracle Mineral Solution or Master Mineral Solution) and CDs (Chloride dioxide solution or German: Chlordioxidlösung - CDL) are two different starting products for the generation of gaseous chlorine dioxide, which is offered in alternative medical circles as a "cure" for various diseases, including COVID-19. However, there is no scientific evidence of the claimed beneficial effects of chlorine dioxide, which is a gas that can cause burns and symptoms of poisoning.

Keine Wirkung gegen COVID-19 und begründeter Verdacht auf schädliche Wirkungen.

Three different test methods for the detection of COVID-19 are currently in use in Austria: PCR (polymerase chain reaction) tests, antibody tests and antigen tests.

Also in the future, we want to continue to inform our applicants of marketing authorisation procedures with Austria as RMS with relevant news from the committees or exciting innovations such as the slot application via our eServices!